In Vitro Pharmacodynamics of Levofloxacin and Other Aerosolized Antibiotics Under Multiple Conditions Relevant to Chronic Pulmonary Infection in Cystic Fibrosis

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2009 Oct 7

PMID 19805554

Citations 24

Authors

Paula King

Olga Lomovskaya

David C Griffith

Jane L Burns

Michael N Dudley

Affiliations

Soon will be listed here.

Abstract

The inhalational administration of antibiotics can provide high concentrations locally in the lungs of cystic fibrosis patients and, thus, can be useful for the treatment of chronic bacterial infections. The present study evaluated the in vitro activities of levofloxacin, ciprofloxacin, tobramycin, amikacin, and aztreonam against clinical isolates of Pseudomonas aeruginosa, Burkholderia cepacia complex, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and Staphylococcus aureus from cystic fibrosis patients. Levofloxacin was the most potent antibiotic against all cystic fibrosis isolates tested, with MIC(90)s ranging from 8 to 32 microg/ml. Levofloxacin was more potent than the aminoglycosides and aztreonam against P. aeruginosa biofilms. Time-kill assays with drug concentrations achievable in sputum following aerosol administration showed that levofloxacin had the most rapid rate of killing among mucoid and nonmucoid isolates of P. aeruginosa. In contrast to tobramycin, the bactericidal activity of levofloxacin was not affected by sputum from cystic fibrosis patients. The results of the study show that the high concentrations of levofloxacin readily achievable in the lung following aerosol delivery may be useful for the management of pulmonary infections in patients with cystic fibrosis.

Citing Articles

Development and Characterization of Spray-Dried Combined Levofloxacin-Ambroxol Dry Powder Inhaler Formulation.

Suraweera R, Spann K, Izake E, Wells T, Wang X, Islam N Pharmaceutics. 2025; 16(12.

PMID: 39771486 PMC: 11728515. DOI: 10.3390/pharmaceutics16121506.

Stenotrophomonas maltophilia in people with Cystic Fibrosis: a systematic review of prevalence, risk factors and management.

Terlizzi V, Tomaselli M, Giacomini G, Dalpiaz I, Chiappini E Eur J Clin Microbiol Infect Dis. 2023; 42(11):1285-1296.

PMID: 37728793 PMC: 10587323. DOI: 10.1007/s10096-023-04648-z.

Current and Emerging Inhaled Antibiotics for Chronic Pulmonary and Infections in Cystic Fibrosis.

Li D, Schneider-Futschik E Antibiotics (Basel). 2023; 12(3).

PMID: 36978351 PMC: 10044129. DOI: 10.3390/antibiotics12030484.

Biofilm Formation by in the Specific Context of Cystic Fibrosis.

Jean-Pierre V, Boudet A, Sorlin P, Menetrey Q, Chiron R, Lavigne J Int J Mol Sci. 2023; 24(1).

PMID: 36614040 PMC: 9820612. DOI: 10.3390/ijms24010597.

Deposition of Inhaled Levofloxacin in Cystic Fibrosis Lungs Assessed by Functional Respiratory Imaging.

Schwarz C, Procaccianti C, Mignot B, Sadafi H, Schwenck N, Murgia X Pharmaceutics. 2021; 13(12).

PMID: 34959333 PMC: 8708197. DOI: 10.3390/pharmaceutics13122051.

References

Hoban D, Bouchillon S, Johnson J, Zhanel G, Butler D, Miller L . Comparative in vitro potency of gemifloxacin and fluoroquinolones against recent European clinical isolates from a global surveillance study. Eur J Clin Microbiol Infect Dis. 2002; 20(11):814-9. DOI: 10.1007/s100960100604. View

Beringer P, Vinks A, Jelliffe R, Shapiro B . Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration. Antimicrob Agents Chemother. 2000; 44(4):809-13. PMC: 89775. DOI: 10.1128/AAC.44.4.809-813.2000. View

Drusano G . Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol. 2004; 2(4):289-300. DOI: 10.1038/nrmicro862. View

McKnight A, Shaw A, Goldsmith C, Clarke L, Millar B, McCaughan J . Comparison of in vitro susceptibilities to levofloxacin and ciprofloxacin with Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolated from cystic fibrosis patients in Northern Ireland. Br J Biomed Sci. 2005; 62(1):30-2. DOI: 10.1080/09674845.2005.11978067. View

Golini G, Favari F, Marchetti F, Fontana R . Bacteriostatic and bactericidal activity of levofloxacin against clinical isolates from cystic fibrosis patients. Eur J Clin Microbiol Infect Dis. 2004; 23(10):798-800. DOI: 10.1007/s10096-004-1216-3. View

Hoffman L, DArgenio D, MacCoss M, Zhang Z, Jones R, Miller S . Aminoglycoside antibiotics induce bacterial biofilm formation. Nature. 2005; 436(7054):1171-5. DOI: 10.1038/nature03912. View

Burns J . Emergence of new pathogens in CF: the devil we know or the devil we don't know?. J Pediatr. 2002; 140(3):283-4. DOI: 10.1067/mpd.2002.123625. View

Ishida H, Ishida Y, Kurosaka Y, Otani T, Sato K, Kobayashi H . In vitro and in vivo activities of levofloxacin against biofilm-producing Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1998; 42(7):1641-5. PMC: 105659. DOI: 10.1128/AAC.42.7.1641. View

Mendelman P, Smith A, Levy J, Weber A, Ramsey B, Davis R . Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am Rev Respir Dis. 1985; 132(4):761-5. DOI: 10.1164/arrd.1985.132.4.761. View

10.

Burns J, Van Dalfsen J, Shawar R, Otto K, Garber R, Quan J . Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis. 1999; 179(5):1190-6. DOI: 10.1086/314727. View

11.

Dasenbrook E, Merlo C, Diener-West M, Lechtzin N, Boyle M . Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med. 2008; 178(8):814-21. DOI: 10.1164/rccm.200802-327OC. View

12.

Van Bambeke F, Michot J, Van Eldere J, Tulkens P . Quinolones in 2005: an update. Clin Microbiol Infect. 2005; 11(4):256-80. DOI: 10.1111/j.1469-0691.2005.01131.x. View

13.

FitzSimmons S . The changing epidemiology of cystic fibrosis. J Pediatr. 1993; 122(1):1-9. DOI: 10.1016/s0022-3476(05)83478-x. View

14.

Gibson R, Retsch-Bogart G, Oermann C, Milla C, Pilewski J, Daines C . Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr Pulmonol. 2006; 41(7):656-65. DOI: 10.1002/ppul.20429. View

15.

Mah T, Pitts B, Pellock B, Walker G, Stewart P, OToole G . A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature. 2003; 426(6964):306-10. DOI: 10.1038/nature02122. View

16.

Lomovskaya O, Lee A, Hoshino K, Ishida H, Mistry A, Warren M . Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1999; 43(6):1340-6. PMC: 89275. DOI: 10.1128/AAC.43.6.1340. View

17.

Miller M, Gilligan P . Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis. J Clin Microbiol. 2003; 41(9):4009-15. PMC: 193835. DOI: 10.1128/JCM.41.9.4009-4015.2003. View

18.

Gillespie T, Masterton R . Investigation into the selection frequency of resistant mutants and the bacterial kill rate by levofloxacin and ciprofloxacin in non-mucoid Pseudomonas aeruginosa isolates from cystic fibrosis patients. Int J Antimicrob Agents. 2002; 19(5):377-82. DOI: 10.1016/s0924-8579(02)00017-1. View

19.

Lechtzin N, John M, Irizarry R, Merlo C, Diette G, Boyle M . Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa. Respiration. 2005; 73(1):27-33. DOI: 10.1159/000087686. View

20.

Gales A, Jones R, Andrade S, Sader H . Antimicrobial susceptibility patterns of unusual nonfermentative gram-negative bacilli isolated from Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997-2002). Mem Inst Oswaldo Cruz. 2005; 100(6):571-7. DOI: 10.1590/s0074-02762005000600011. View